Arrowhead to Present at Upcoming Conferences
PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that the
company will make presentations at the following upcoming events.
The Liver Meeting 2015®, 66th Annual Meeting
of the American Association for the Study of Liver Disease (AASLD) –
San Francisco, November 13-17, 2015
November 15, 3:15 p.m. PST – Christine Wooddell, Ph.D., Arrowhead
group leader will deliver an oral presentation titled, “Reductions in
cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic
hepatitis B virus infection implicate integrated DNA in maintaining
circulating HBsAg”
November 16, 8:00 a.m. – 5:30 p.m. PST – Man-Fung Yuen, M.D.,
Ph.D., chair of gastroenterology and hepatology, The University of Hong
Kong, and deputy chief of service, Queen Mary Hospital department of
medicine, Hong Kong, will deliver a late-breaking poster presentation
titled, “ARC-520 produces deep and durable knockdown of viral
antigens and DNA in a phase II study in patients with chronic hepatitis B”
November 16, 6:30 p.m. PST – Arrowhead management will host an Analyst
and Investor Reception to discuss ARC-520 and key data being
presented at the conference
November 17, 8:00 a.m. – 12:00 p.m. PST – Christine Wooddell,
Ph.D., Arrowhead group leader will deliver a poster presentation titled,
“Monthly dosing of ARC-520 in chronically hepatitis B virus infected
chimpanzees produces rapid, deep and durable reductions in circulating
viral antigens”
Jefferies Autumn 2015 Global Healthcare Conference – London, UK,
November 18-19, 2015
November 19, 2:40 p.m. GMT – Chris Anzalone, Ph.D., Arrowhead
president and chief executive officer, will present a company overview
Piper Jaffray 27th Annual Healthcare Conference – New York,
December 1-2, 2015
December 2, 3:00 p.m. EST – Chris Anzalone, Ph.D., Arrowhead
president and chief executive officer, will present a company overview
in a fireside chat with Ted Tenthoff, senior research analyst, Piper
Jaffray
HEP DART 2015 – Wailea, Hawaii, December 6-10, 2015
December 2, 6:40 p.m. HST – Bruce Given, M.D., Arrowhead chief
operating officer, will deliver an oral presentation titled, “New
insights on HBV biology from the ARC-520 development program”
December 8, 4:00 – 5:30 p.m. HST – Christine Wooddell, Ph.D.,
Arrowhead group leader will deliver a poster presentation titled, “Sustained
reduction in HBsAg, HBV DNA and HBeAg seroconversion in a chronically
HBV-infected chimpanzee treated with nucleoside analog/ARC-520
combination therapy”
Links to the webcasts and copies of presentation materials, if
available, can be accessed by visiting the Events section of the
company’s website at http://ir.arrowheadresearch.com/events.cfm.
About ARC-520
Arrowhead’s RNAi-based candidate ARC-520 is being investigated in the
treatment of chronic HBV infection. The small interfering RNAs (siRNAs)
in ARC-520 intervene at the mRNA level, upstream of the reverse
transcription process where current standard of care nucleotide and
nucleoside analogues act. Arrowhead is investigating ARC-520
specifically to determine if it can be used to achieve a functional
cure, which is an immune clearant state characterized by hepatitis B
s-antigen negative serum with or without sero-conversion. Arrowhead is
conducting Phase 2b multiple dose and combination studies in chronic HBV
patients. Approximately 350-400 million people worldwide are chronically
infected with the hepatitis B virus, which can lead to cirrhosis of the
liver and is responsible for 80% of primary liver cancers globally.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate™ delivery platform to develop targeted
drugs based on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead’s pipeline includes ARC-520 and ARC-521
for chronic hepatitis B virus, ARC-AAT for liver disease associated with
alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and
thromboembolic diseases, and ARC-HIF2 for renal cell carcinoma.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including our ability to finance our operations, the
future success of our scientific studies, our ability to successfully
develop drug candidates, the timing for starting and completing clinical
trials, rapid technological change in our markets, and the enforcement
of our intellectual property rights. Arrowhead Research Corporation’s
most recent Annual Report on Form 10-K and subsequent Quarterly Reports
on Form 10-Q discuss some of the important risk factors that may affect
our business, results of operations and financial condition. We assume
no obligation to update or revise forward-looking statements to reflect
new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research
Corporation.
Source: Arrowhead Research Corporation
View source version on businesswire.com: http://www.businesswire.com/news/home/20151111005352/en/
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor
Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowres.com
or
Media:
Russo
Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com
Source: Arrowhead Research Corporation
News Provided by Acquire Media